CDER Drug Safety Website Model Includes Elidel; Novartis Objects
Executive Summary
Novartis objects to the inclusion of its eczema therapy Elidel in FDA's drug safety website model
You may also be interested in...
FDA Phasing In Restructuring Of Drug Office; Move To White Oak Postponed
FDA is proceeding with the restructuring of the Office of New Drugs ahead of a formal switch to the new organization in September
FDA Phasing In Restructuring Of Drug Office; Move To White Oak Postponed
FDA is proceeding with the restructuring of the Office of New Drugs ahead of a formal switch to the new organization in September
FDA Rx Safety Website Will Include Drugs With Emerging Off-Label Issues
FDA's "Drug Watch" website will include safety information on drugs that have emerging safety signals for off-label uses